Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.
Can AB-1009 reshape treatment for late-onset Pompe? AskBio prepares for first patient in U.S.
AskBio’s AB-1009 gene therapy for late-onset Pompe secures FDA IND clearance. Find out what this milestone means for AAV innovation and patient outlook.
TheraTears expands into digital eye strain relief: What the launch signals for OTC eye care
TheraTears adds eyelid wipes and preservative-free drops for screen fatigue. Find out what this expansion means for OTC dry eye care and consumer trends.
How Biocorneum’s new bruise kit reflects a wider shift in aesthetic medicine aftercare
Explore how Biocorneum’s dual-action bruise care system could reshape post-procedure recovery in aesthetic medicine. Read the strategic analysis now.
Why AIROS Medical’s extended warranty could reshape buyer expectations in lymphedema care
Find out how AIROS Medical’s five-year warranty on compression devices may shift durability standards and procurement expectations in lymphedema care.
Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?
AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.
Can Lynx Analytics’ Lumen framework reshape AI-driven decision-making in life sciences?
Lynx Analytics has introduced Lumen, a dedicated agentic artificial intelligence framework designed to support complex decision-making across life sciences workflows. The launch was anchored by a real-world deployment at AstraZeneca, where a custom-built application called IlluminAI is now embedded in the oncology team’s brand planning process across international markets. The framework is positioned as a […]
GT Medical Technologies’ BRIDGES trial begins enrollment, testing GammaTile in newly diagnosed glioblastoma patients
GT Medical Technologies has announced the first patient enrollments in its BRIDGES trial, a randomized clinical study assessing the use of GammaTile therapy in newly diagnosed glioblastoma. The trial introduces GammaTile at the time of initial tumor resection, marking a notable shift from the conventional glioblastoma radiation timeline, which typically delays radiation until several weeks […]
Robotic cochlear implants approved for kids: Is iotaSOFT reshaping pediatric ENT standards?
iotaMotion, Inc. has received U.S. Food and Drug Administration 510(k) clearance to expand the approved use of its iotaSOFT Robotic-Assisted Cochlear Implant Insertion System for children as young as four years old. This regulatory milestone makes the iotaSOFT system the first robotic-assisted cochlear insertion platform authorized for use in school-aged pediatric patients, expanding access to […]
Cereno Scientific’s CS014 shows antithrombotic effect without bleeding risk in new HDAC study
Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with […]